Cochrane · systematic review · CD003139
High‐dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer
Farquhar, C, Marjoribanks, J, Lethaby, A, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 4 · 100%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
High‐dose chemotherapy versus chemotherapy without bone marrow transplant or stem cell rescue
Population: women with early poor prognosis breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival at 5‐year High‐dose chemotherapy vs chemotherapy without bone marrow transplant or stem cell rescue | RR 1 [0.96, 1.04] | 8 studies · 3566 participants | High |
Event‐free survival at 5‐year High‐dose chemotherapy vs chemotherapy without bone marrow transplant or stem cell rescue | RR 1.04 [0.99, 1.1] | 8 studies · 3566 participants | High |
Treatment‐related mortality High‐dose chemotherapy vs chemotherapy without bone marrow transplant or stem cell rescue | RR 7.97 [3.99, 15.92] | 14 studies · 5600 participants | High |
Second cancers at 4 ‐ 9‐year median High‐dose chemotherapy vs chemotherapy without bone marrow transplant or stem cell rescue | RR 1.25 [0.9, 1.73] | 7 studies · 3423 participants | High |